https://www.marketscreener.com/quote/stock/CHROMADEX-CORPORATION-27343156/news/ChromaDex-Shares-Promising-Findings-from-Clinical-Study-Demonstrating-Oral-Supplementation-with-Nico-42627880/
0
0
ChromaDex Shares Promising Findings from Clinical Study Demonstrating Oral Supplementation with Nicotinamide Riboside (NR) Increased Nicotinamide Adenine Dinucleotide Levels in the Brain and Positively Impacted Neurodegenerative Biomarkers - Marketscreener.com
12/28/22 at 1:30pm
Organization
Marketscreener.com
Author
MarketScreener
Details
59 words
Summarize
Vitamins & Supplements Health Clinical Study Demonstrating Oral Supplementation with Nicotinamide Riboside ChromaDex Shares ChromaDex Corp. Positively Impacted Neurodegenerative Biomarkers NAD+ Niagen
ChromaDex Corp. , a global bioscience company dedicated to healthy aging, announced promising new findings based on a previously published clinical trial of company's proprietary Niagen ingredient ,... | December 28, 2022
Create an account or login to join the discussion